Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy
Consultation with Manipulator in Medical Radiology and a radiotherapistConsultation with a radiotherapist
Consultation with Manipulator in Medical Radiology and a radiotherapist: Weekly consultation with Manipulator in Medical Radiology and a radiotherapist
Consultation with a radiotherapist: Weekly consultation with a radiotherapist
Study summary
To our knowledge, the investigators have not found any scientific article dealing with cooperation between radiation oncologists and medical radiation technologists in the context of monitoring patients undergoing radiotherapy. Cooperation protocols between health professionals are in progress but concern mainly technical procedures (ultrasound, laserthermal sessions).
This study aims to evaluate whether MERMs, after training by physicians, can monitor clinical signs (for usual well-described toxicities) during treatment via a dedicated consultation.
This approach participates in the development of new professions and cooperation protocols between health professionals. This mission of accompaniment on a dedicated time would make it possible to develop the caring role of the medical electroradiology manipulator.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient \> 18 years;
* Patient with malignant or benign brain or upper aerodigestive tract (ADT) tumor candidate for proton therapy;
* WHO score \< 2
* Mastery of the French language;
* Patient affiliated with a social security system;
* Signature of informed consent prior to any specific procedure related to the study.
Exclusion Criteria:
* Patient with another cancer previously treated with radiation therapy;
* Simultaneous participation in a therapeutic clinical trial;
* Patient deprived of liberty or under guardianship;
* Any associated medical or psychological condition that may compromise the patient's ability to participate in the study
* Patient unable to undergo trial monitoring for geographical, social or psychopathological reasons.
Primary outcome measure(s)
Proportion of patients with at least one toxicity requiring intervention — 3 weeks
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
